Regulators have also advised against the long-term use of opioids in non-cancer pain.
Patients who take medicines containing opioids for non-cancer pain will now be given stronger warnings about the risk of dependence and addiction, the Medicines and Healthcare products Regulatory Agency (MHRA) announced.
Healthcare professionals have been asked by the MHRA to discuss these warnings with any patient taking or planning to take an opioid-containing medicine like Tramadol, Codeine, or Oramorph.
This includes the agreement of a treatment plan, including how long treatment should last, to minimize the risk of dependence.
Additional warnings are now to be added to the patient information leaflet, making it clear that the medicine is an opioid and addictive. Also, there can be withdrawal symptoms if people stop taking it suddenly.
Following concerns raised about the prescribing rates of opioids in the UK, the Opioid Expert Working Group (EWG) of the Commission on Human Medicines (CHM) developed a set of recommendations to improve the information for prescribers and patients and to protect public health.
While the CHM continues to consider opioids as important and effective medicines in the treatment of short-term pain relief, they have advised against their long-term use in the treatment of non-cancer pain, due to the risk of dependence and addiction.
The MHRA Director of Vigilance and Risk Management of Medicines, Sarah Branch said: “Patient safety is our highest priority and that is why we continually monitor the benefits and risks of opioid medicines. Last year, we announced that opioid-containing medicine packaging must carry warnings.
“Now, we are strengthening those warnings to ensure that opioid medicines are supplied with consistent information on how to manage the risk of addiction. This is a further step forward in helping to promote the safe use of these pain-relieving medicines.”